Patent ID: 7803951

Claim:
A compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein: ring A is selected from the group consisting of: 6-10 membered aryl and 5-10 membered heteroaryl, said heteroaryl containing from 1-4 heteroatoms, 0-2 of which are O or S atoms, and 0-4 of which are N; Y is present or absent, and when present, represents O, S, NH or CH 2 ; X is present or absent, and when present, represents O or CH 2 ; each R 1 is H or is selected from the group consisting of: (a) halo, OH, CO 2 R 4 , SO p R 5 , CN, NO 2 C(O)NR 6 R 7 or NR 6 R 7 ; (b) C 1-10 alkyl, C(O)C 1-6 alkyl or OC 1-6 alkyl, the alkyl portions being optionally substituted with: (1) 1-5 halo groups, up to perhalo, and 1-2 groups selected from OH, CO 2 R 4 , SO p R 5 , CN, NO 2 C(O)NR 6 R 7 , NR 6 R 7 and phenyl optionally substituted with 1-3 halo groups and 1-2 groups selected from: OH, C 1-3 alkyl, haloC 1-3 alkyl, CN, OC 1-3 alkyl and OhaloC 1-3 alkyl; (c) a 6-10 membered aryl or aryloxy group, said groups being optionally substituted with 1-3 halo groups and 1-2 groups selected from: OH, C 1-3 alkyl, haloC 1-3 alkyl, CN, OC 1-3 alkyl and OhaloC 1-3 alkyl; R 2 is C 1-10 alkyl or aryl optionally substituted with 1-3 groups selected from (a), (b) and (c) above; R 3 represents CH 2 CH 2 CO 2 R 4 , CH 2 CH(OH)CO 2 R 4 , CH 2 CF 2 CO 2 R 4 or 5-tetrazolyl; R 4 is H or C 1-6 alkyl, and R 5 represents a member selected from the group consisting of: C 1-10 alkyl, Aryl or Ar—C 1-10 alkyl, said C 1-10 alkyl, Aryl and Ar—C 1-10 alkyl being optionally substituted with 1-3 halo groups; R 6 and R 7 each independently represent H or C 1-3 alkyl, R 8 is selected from the group consisting of: H, OH, C 1-3 alkyl, haloC 1-3 alkyl, CN, OC 1-3 alkyl and OhaloC 1-3 alkyl, and p is 0, 1 or 2.